Inne Raises Undisclosed Round Backed by Swiss Health Ventures for At-Home Hormone Tracking

Inne Receives Investment from Swiss Health Ventures

Inne, a Berlin-based femtech company, has raised an undisclosed round with participation from Swiss Health Ventures. The funding date is October 5, 2026. The round is denominated in EUR; the amount was not disclosed, and no lead investor was named.

What Inne Does

Inne is a femtech company founded in 2016 by Eirini Rapti and Hicham Ratnani. Its CE-certified at-home minilab tracks progesterone through saliva-based measurements.

The minilab is paired with an app that turns the readings into personalised cycle and fertility insights. According to the company, the system is used for:

• Hormone-free contraception
• When trying for a baby
• Understanding hormonal shifts across life stages, including perimenopause and menopause

Company Details

• Name: Inne
• Headquarters: Berlin, Germany
• Founded: 2016
• Founders: Eirini Rapti and Hicham Ratnani
• Sector: Femtech
• Product: CE-certified at-home minilab for saliva-based progesterone tracking, paired with an app for personalised cycle and fertility insights

The Investor

Swiss Health Ventures participated in the round. No lead investor was identified in the funding payload, and no additional investors were named.

Why This Matters in Femtech and Hormone Health

Hormone tracking has traditionally relied on clinical testing or indirect symptom tracking. Inne's approach centers on saliva-based progesterone measurement through a CE-certified at-home minilab, combined with software that translates readings into personalised insights.

The company's stated use cases span contraception, fertility, and hormonal transitions including perimenopause and menopause, positioning the product across multiple life stages rather than a single use case.

Acquisition Angle

For acquirers and strategic investors in femtech, diagnostics, and consumer health, Inne represents a hardware-plus-software asset with regulatory certification (CE) and a multi-use-case positioning. The combination of an at-home measurement device and a companion app creates recurring engagement potential across contraception, fertility, and menopause-related needs.

Swiss Health Ventures' participation adds healthcare-focused investment backing to the round.

Summary

• Company: Inne
• Headquarters: Berlin, Germany
• Founded: 2016
• Founders: Eirini Rapti and Hicham Ratnani
• Round: Undisclosed
• Investor: Swiss Health Ventures
• Funding date: October 5, 2026
• Currency: EUR
• Amount: Not disclosed
• Lead investor: Not disclosed

Key Takeaways

Inne's undisclosed round, backed by Swiss Health Ventures, supports a CE-certified at-home minilab that measures progesterone via saliva and pairs with an app for personalised cycle and fertility insights. The system addresses hormone-free contraception, conception support, and hormonal shifts across life stages including perimenopause and menopause. Founded in 2016 by Eirini Rapti and Hicham Ratnani, the Berlin-based company operates at the intersection of femtech hardware, diagnostics, and consumer health software.